Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95%


- Adipose Delivery Platform Achieved Single Dose... | June 1, 2023

Related Keywords

Miami ,Florida ,United States ,Christopher Anzalone ,Kira Goldberg ,Matthias Salathe ,Michael Benatar ,Nasdaq ,Research Development Rd Day ,Langone Medical Center ,Md University Of Kansas Medical Center ,Arrowhead Pharmaceuticals Inc ,Arrowhead Pharmaceuticals ,Miami Miller School ,Kansas Medical Center ,Medical Center ,Harbor Statement ,Private Securities Litigation Reform Act ,Nc Stock Exchange ,News ,Information ,Press Release ,Few ,Linical ,Data ,N ,Show ,Ontinued ,Nose ,Response ,Ith ,Single ,Inhaled ,F ,84 ,G ,Chieving ,Sean ,Knockdown ,End ,Tax ,Adipose ,Delivery ,Platform ,Chieved ,Ingle Arwr Us04280a1007 ,